A new neuromodulation method in chronic migraine; non-ınvasive pulsed radiofrequency, a single-blinded, randomised, controlled trial

• Published in: Irish journal of medical science Vol. 193; no. 3; pp. 1487 - 1493
• Main Authors: Perdecioğlu, Gevher Rabia Genç, Ateş, Mehlika Panpallı, Yürük, Damla, Can, Ezgi, Yıldız, Gökhan, Akkaya, Ömer Taylan
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2024
• Subjects: Adult; Chronic Disease; Family Medicine; Female; General Practice; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Migraine Disorders - therapy; Original Article; Pain Measurement; Pulsed Radiofrequency Treatment - methods; Single-Blind Method; Treatment Outcome; Chronic migraine; Non-invasive pused radiofrequency; Pulsed radiofrequency; Migraine treatment; Greater occipital nerve block
• ISSN: 0021-1265; 1863-4362
• DOI: 10.1007/s11845-023-03598-x

Objective Non-invasive pulsed radiofrequency (NipRF) therapy, a neuromodulation method for peripheral nerves, is a new treatment modality for pain. We aimed to show the changes in pain severity and frequency per month in chronic migraine with NipRF treatment. Methods We treated patients diagnosed with chronic migraine according to the International Classification of Headache Disorders III beta diagnostic criteria. In half of the patients, we applied pulsed radiofrequency (pRF) treatment with transcutaneous electrodes to the greater occipital nerve (GON) trace. In the other half, we applied the GON block under ultrasound guidance. The Migraine Disability Assessment Scale (MIDAS) was administered to the participants, and those with scores > 2 were included in the study. Pain intensity and frequency were evaluated using the visual analog scale (VAS) and a headache diary completed before and 4 weeks after treatment. Results When both groups were compared, the pre- and post-treatment VAS scores and headache frequencies were similar. Comparing the pre-treatment and post-treatment values within the groups, VAS scores and headache frequency decreased significantly after treatment in both groups (p < 0.001). Conclusion In this study, we observed that NipRF treatment is safe and effective for treating chronic migraine. Pain intensity and frequency decreased with NipRF treatment, similar to that in the GON block group. Clinical Trials Registration Number : NCT05499689, Date: 08/11/2022.